Biology Reference
In-Depth Information
6. Talving P et al (2010) Erythropoiesis stimulat-
ing agent administration improves survival after
severe traumatic brain injury: a matched case
control study. Ann Surg 251:1-4
7. Corwin HL et al (2002) Efficacy of recombi-
nant human erythropoietin in critically ill
patients: a randomized controlled trial. JAMA
288:2827-2835
8. Corwin HL et al (2007) Efficacy and safety of
epoetin alpha in critically ill patients. NEJM
357:965-976
9. Lin FK et al (1985) Cloning and expression of
the human erythropoietin gene. Proc Natl
Acad Sci U S A 82:7580-7584
10. Brines M (2010) The therapeutic potential of
erythropoiesis-stimulating agents for tissue
protection: a tale of two receptors. Blood Purif
29:86-92
11. Sola A et al (2005) Erythropoietin after focal
cerebral ischemia activates the Janus kinase-
signal transducer and activator of transcription
signaling pathway and improves brain injury in
postnatal day 7 rats. Pediatr Res 57:481-487
12. Kawakami M et al (2000) Erythropoietin
inhibits calcium-induced neurotransmitter
release from clonal neuronal cells. Biochem
Biophys Res Commun 279:293-297
13. Kawakami M et al (2001) Erythropoietin
receptor-mediated inhibition of exocytotic
glutamate release confers neuroprotection dur-
ing chemical ischemia. J Biol Chem 276:
39469-39475
14. Solaroglu I et al (2003) Erythropoietin pre-
vents ischemia-reperfusion from inducing oxi-
dative damage in fetal rat brain. Childs Nerv
Syst 19:19-22
15. Wu Y et al (2010) Increased expression of
erythropoietin receptor in 1-methyl-4-phe-
nyl-1, 2, 3, 6-tetrahydropyridine-induced
Parkinsonian model. Physiol Res 59:281-287
16. Wang L et al (2004) Treatment of stroke with
erythropoietin enhances neurogenesis and
angiogenesis and improves neurological func-
tion in rats. Stroke 35:1732-1737
17. Brines ML et al (2000) Erythropoietin crosses
the blood-brain barrier to protect against
experimental brain injury. Proc Natl Acad Sci
U S A 97:10526-10531
18. Meng Y et al (2011) Dose-dependent neu-
rorestorative effects of delayed treatment of
traumatic brain injury with recombinant human
erythropoietin in rats. J Neurosurg 115:
550-560
19. Xiong Y et al (2007) Role of gender in out-
come after traumatic brain injury and thera-
peutic effect of erythropoietin in mice. Brain
Res 1185:301-312
20. Yatsiv I et al (2005) Erythropoietin is neuro-
protective, improves functional recovery, and
reduces neuronal apoptosis and inflammation
in a rodent model of experimental closed head
injury. FASEB J 19:1701-1703
21. Zhu L et al (2009) Erythropoietin prevents
zinc accumulation and neuronal death after
traumatic brain injury in rat hippocampus:
in vitro and in vivo studies. Brain Res
1289:96-105
22. Lu D et al (2005) Erythropoietin enhances
neurogenesis and restores spatial memory in
rats after traumatic brain injury. J Neurotrauma
22:1011-1017
23. Mahmood A et al (2007) Treatment of trau-
matic brain injury in rats with erythropoietin
and carbamylated erythropoietin. J Neurosurg
107:392-397
24. Bohlius J et al (2009) Recombinant human
erythropoiesis-stimulating agents and mortal-
ity in patients with cancer: a meta-analysis of
randomised trials. Lancet 373:1532-1542
25. Bohlius JF et al (2005) Effectiveness of eryth-
ropoietin in the treatment of patients with
malignancies: methods and preliminary results
of a Cochrane review. Best Pract Res Clin
Haematol 18:449-454
26. Xiong Y et al (2010) Delayed administration of
erythropoietin reducing hippocampal cell loss,
enhancing angiogenesis and neurogenesis, and
improving functional outcome following trau-
matic brain injury in rats: comparison of treat-
ment with single and triple dose. J Neurosurg
113:598-608
27. Leist M et al (2004) Derivatives of erythropoi-
etin that are tissue protective but not erythro-
poietic. Science 305:239-242
28. Brines M et al (2008) Nonerythropoietic, tis-
sue-protective peptides derived from the ter-
tiary structure of erythropoietin. Proc Natl
Acad Sci U S A 105:10925-10930
29. Pankratova S et al (2010) Neuroprotective
properties of a novel, non-haematopoietic ago-
nist of the erythropoietin receptor. Brain
133:2281-2294
30. Brines M et al (2004) Erythropoietin mediates
tissue protection through an erythropoietin
and common beta-subunit heteroreceptor.
Proc Natl Acad Sci U S A 101:14907-14912
31. Kanellakis P et al (2010) Darbepoetin-mediated
cardioprotection after myocardial infarction
involves multiple mechanisms independent of
erythropoietin receptor-common beta-chain
heteroreceptor. Br J Pharmacol 160:
2085-2096
32. Satake R et al (1990) Chemical modification of
erythropoietin: an increase in in vitro activity
by guanidination. Biochim Biophys Acta
1038:125-129
33. Erbayraktar S et al (2003) Asialoerythropoietin
is a nonerythropoietic cytokine with broad
neuroprotective activity in vivo. Proc Natl Acad
Sci U S A 100:6741-6746
Search WWH ::
Custom Search